zidebactam   Click here for help

GtoPdb Ligand ID: 10874

Synonyms: WCK-5107 | WCK5107
Compound class: Synthetic organic
Comment: Zidebactam (WCK 5107) is a novel β-lactamase inhibitor [1-2]. It was developed for the treatment of serious infections caused by highly drug-resistant Gram-negative pathogens.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 165.76
Molecular weight 391.12
XLogP -2.56
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C([C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O)NNC(=O)[C@@H]1CCCNC1
Isomeric SMILES O=C([C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O)NNC(=O)[C@@H]1CCCNC1
InChI InChI=1S/C13H21N5O7S/c19-11(8-2-1-5-14-6-8)15-16-12(20)10-4-3-9-7-17(10)13(21)18(9)25-26(22,23)24/h8-10,14H,1-7H2,(H,15,19)(H,16,20)(H,22,23,24)/t8-,9-,10+/m1/s1
No information available.
Summary of Clinical Use Click here for help
Zidebactam (ZID) is being investigated in combination with cefepime (FEP). The combination preparation is named WCK 5222, or FEP-ZID. As of May 2020 this has been tested in a number of Phase 1 studies, in healthy trial subjects only.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02707107 MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers Phase 1 Interventional Wockhardt